- Poster presentation
- Open Access
Omalizumab for severe allergic asthma: a life changing drug?
© Mesonjesi et al; licensee BioMed Central Ltd. 2015
- Published: 23 March 2015
- Asthma Symptom
- Rescue Medication
- Allergic Asthma
Asthma is an airway condition and is associated with significant morbidity and mortality. The recent updates for treatment of asthma recommends omalizumab for use as add-on therapy in adults and children >6 years of age with inadequately controlled severe persistent allergic asthma. Omalizumab, a humanized anti-IgE mAb, specifically binds free IgE. The clinical efficacy of omalizumab has been well documented in a number of clinical trials. In these studies omalizumab reduced exacerbations, asthma symptoms, inhaled corticosteroid and rescue medication use, and improved quality of life. Similar benefits have been reported in observational studies in "real-world" populations of patients. In our clinic we started recently using omalizumab in patients with severe allergic asthma using several biomarkers to monitor the asthma severity like spirometry, exhaled NO (FeNO), asthma control test (ACT), rhinitis control test. The data are still being collected since most of the patients are within the 16 week period of evaluation. We want to present one case from them that has completed the 16 week of treatment.
A young woman 20 year-old, who suffered a lifetime history of severe allergic asthma since 3 years of age. She had several episodes of near fatal asthma the last one last winter. She is allergic to house dust mites, with continuous need for the rescue medication, and any kind of physical activity even walking for long distances is impossible for her. She couldn’t follow the College because of the disease. Omalizumab was started on June 2014, 150 mg every 4 weeks, as add on therapy to fluticasone-salmeterol 250/50mcg. On week 16 she had better scores in different biomarkers: ACT: 17 from 15 on day 0, spirometry: FEV1 1.62 (57%) on day 0 to 1.77 (64.5%) on week 16, and FeNO: 16 ppb on day 0 to 14ppb on week 16. The patient is feeling much better; she had no exacerbation and no need for the rescue medication. She is able to walk for the first time long distances without having an asthma attack.
Omalizumab is effective in reducing asthma exacerbations and hospitalisations as an adjunctive therapy to inhaled steroids. Omalizumab is found to be generally safe and well-tolerated. Our patient had no side effects. We observed small changes in the biomarkers but the therapy looks very promising for the future.
Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.